The concept of using vaccination to eradicate cancer by instructing the immune system to eliminate malignant cells has been pursued for decades with little success. Stimulating an immune response against cancer is more complicated...
Researchers explore mechanisms of chemotherapy-related neurotoxicity at the AACR Annual Meeting 2023.
The treatment of cutaneous melanoma has been profoundly transformed by the advent of targeted therapy and immunotherapy, which have prolonged survival in some patients with metastatic disease and reduced the risk of relapse in...
Men are increasingly opting to put off treatment for low-risk prostate cancer, and doctors say it’s a good thing.
The AACR Annual Meeting 2023 set a new record this year with the number of clinical trial abstracts submitted to the meeting. More than 240 abstracts were showcased over the course of the meeting...
Earlier this month, over 21,000 researchers, clinicians, patients, and other stakeholders gathered at the AACR Annual Meeting 2023 to discuss the latest advances across the continuum of cancer research—from basic science to clinical research...
Historically, most cancer drugs have been tested separately in adults and children. For the approval of new drugs for children, researchers must ensure that doses are properly recalculated and new side effects do not...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in the plenary hall and virtually to watch the Opening Plenary Session of the AACR Annual...
People of African descent who receive genetic testing have fewer actionable mutations compared with white people—suggesting fewer available treatment options.
New study finds drug combination after surgery helps prevent recurrence in liver cancer patients.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 54,000 members worldwide drive progress against cancer.
Donate Now